NASDAQ:NUVA NuVasive - NUVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.08 +0.27 (+0.73%) (As of 03/24/2023 08:51 PM ET) Add Compare Share Share Today's Range$36.53▼$37.2850-Day Range$36.81▼$48.1252-Week Range$35.17▼$60.47Volume951,800 shsAverage Volume1.07 million shsMarket Capitalization$1.94 billionP/E Ratio52.23Dividend YieldN/APrice Target$50.77 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NuVasive MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside36.9% Upside$50.77 Price TargetShort InterestBearish8.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth18.81%From $2.02 to $2.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.77 out of 5 starsMedical Sector65th out of 995 stocksSurgical & Medical Instruments Industry6th out of 103 stocks 4.1 Analyst's Opinion Consensus RatingNuVasive has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.77, NuVasive has a forecasted upside of 36.9% from its current price of $37.08.Amount of Analyst CoverageNuVasive has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.68% of the outstanding shares of NuVasive have been sold short.Short Interest Ratio / Days to CoverNuVasive has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuVasive has recently increased by 17.97%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuVasive does not currently pay a dividend.Dividend GrowthNuVasive does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVA. Previous Next 1.9 News and Social Media Coverage News SentimentNuVasive has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NuVasive this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added NuVasive to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuVasive insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.47% of the stock of NuVasive is held by insiders. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for NuVasive are expected to grow by 18.81% in the coming year, from $2.02 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuVasive is 52.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.11.Price to Earnings Ratio vs. SectorThe P/E ratio of NuVasive is 52.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.05.Price to Earnings Growth RatioNuVasive has a PEG Ratio of 0.92. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNuVasive has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuVasive (NASDAQ:NUVA) StockNuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.Read More Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVA Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comGlobus Medical (GMED) to Gain From NUVA Deal Amid Rising CostsMarch 21, 2023 | finance.yahoo.comNuVasive's (NUVA) Precice System Cleared for Pediatric PatientsMarch 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 20, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Coverage Initiated at StockNews.comMarch 17, 2023 | finance.yahoo.comNuVasive (NUVA), GMED Merger Aids, Macro Woes Mar GrowthMarch 14, 2023 | finance.yahoo.comNuVasive to Participate in Upcoming Spine Society Annual ConferencesMarch 13, 2023 | finance.yahoo.comNuVasive Celebrates 20-Year Milestone of the XLIF ProcedureMarch 10, 2023 | marketwatch.comSpinal Fusion Devices Market Outlook and Forecast to 2028 with Top Countries DataMarch 27, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 8, 2023 | marketwatch.comPrestige Cervical Disc Market : Industry Demand, Key Players Strategies, Size, SWOT Analysis and Forecast 2028March 8, 2023 | marketwatch.comExploring the Biological Implants Market: Progresses for Huge Profits during 2023-2028February 24, 2023 | washingtonpost.comNuVasive: Q4 Earnings SnapshotFebruary 24, 2023 | msn.comNuVasive Non-GAAP EPS of $0.43 misses by $0.08, revenue of $305.4M misses by $5.61MFebruary 24, 2023 | investing.comNuVasive PT Raised to $53 at BarclaysFebruary 23, 2023 | finance.yahoo.comNuVasive (NUVA) Q4 Earnings Miss Estimates, Margins DownFebruary 22, 2023 | finance.yahoo.comNuVasive (NUVA) Q4 Earnings and Revenues Miss EstimatesFebruary 12, 2023 | seekingalpha.comGlobus Medical: Does The NuVasive Merger Make Sense?February 9, 2023 | finance.yahoo.comGlobus Medical to merge with NuVasive in a proposed $3.1B all-stock dealFebruary 9, 2023 | benzinga.comGlobus Medical-NuVasive Deal To Accelerate Globalization Strategy, Target $50B Musculoskeletal MarketFebruary 9, 2023 | finance.yahoo.comGlobus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient CareFebruary 9, 2023 | finance.yahoo.comUPDATE 2-Globus Medical to buy NuVasive in deal valued at about $3 billionFebruary 9, 2023 | finance.yahoo.comNuVasive rallies while Globus Medical moves down after companies announce all-stock merger dealFebruary 9, 2023 | finance.yahoo.comGlobus Medical to Buy NuVasive in $3.1 Billion DealJanuary 30, 2023 | finance.yahoo.comNuVasive Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2022 ResultsJanuary 21, 2023 | marketwatch.comALIF Market : Research Report Analysis by Competitors, Sales, Revenue and Industry Size 2023 To 2028January 21, 2023 | finance.yahoo.comWorldwide Orthopedic Implants Industry to 2031 - Players Include Medtronic Spinal, DJO Global, Arthrex and NuVasiveJanuary 14, 2023 | finance.yahoo.comNuVasive (NASDAQ:NUVA) adds US$89m to market cap in the past 7 days, though investors from three years ago are still down 43%See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVA Company Calendar Last Earnings2/22/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees3,000Year Founded1997Price Target and Rating Average Stock Price Forecast$50.77 High Stock Price Forecast$58.00 Low Stock Price Forecast$44.50 Forecasted Upside/Downside+36.9%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.71 Trailing P/E Ratio52.23 Forward P/E Ratio18.36 P/E Growth0.91Net Income$40.41 million Net Margins3.36% Pretax Margin4.35% Return on Equity12.45% Return on Assets4.76% Debt Debt-to-Equity Ratio0.51 Current Ratio1.21 Quick Ratio0.74 Sales & Book Value Annual Sales$1.20 billion Price / Sales1.61 Cash Flow$5.00 per share Price / Cash Flow7.41 Book Value$16.67 per share Price / Book2.22Miscellaneous Outstanding Shares52,190,000Free Float51,947,000Market Cap$1.94 billion OptionableOptionable Beta1.05 Social Links Key ExecutivesJ. Christopher BarryChief Executive Officer & DirectorDale WolfSenior Vice President-Global OperationsMatthew K. HarbaughChief Financial Officer & Executive Vice PresidentKyle MaloneVice President-Scientific AffairsRyan DonahoeChief Technology Officer & Senior Vice PresidentKey CompetitorsAtriCureNASDAQ:ATRCAlphatecNASDAQ:ATECCardiovascular SystemsNASDAQ:CSIIOrthofix MedicalNASDAQ:OFIXIntegra LifeSciencesNASDAQ:IARTView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 32,363 shares on 3/23/2023Ownership: 0.053%Victory Capital Management Inc.Bought 90,777 shares on 3/10/2023Ownership: 1.396%Voya Investment Management LLCSold 29,488 shares on 2/28/2023Ownership: 0.039%NatixisBought 1,660 shares on 2/24/2023Ownership: 0.003%Teachers Retirement System of The State of KentuckyBought 7,295 shares on 2/22/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions NUVA Stock - Frequently Asked Questions Should I buy or sell NuVasive stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares. View NUVA analyst ratings or view top-rated stocks. What is NuVasive's stock price forecast for 2023? 11 equities research analysts have issued 1-year price targets for NuVasive's shares. Their NUVA share price forecasts range from $44.50 to $58.00. On average, they anticipate the company's stock price to reach $50.77 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts. How have NUVA shares performed in 2023? NuVasive's stock was trading at $41.24 on January 1st, 2023. Since then, NUVA shares have decreased by 10.1% and is now trading at $37.08. View the best growth stocks for 2023 here. When is NuVasive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our NUVA earnings forecast. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, February, 22nd. The medical device company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.08. The medical device company earned $305.45 million during the quarter, compared to analyst estimates of $311.01 million. NuVasive had a trailing twelve-month return on equity of 12.45% and a net margin of 3.36%. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS. What ETFs hold NuVasive's stock? ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Vanguard S&P Small-Cap 600 Value ETF (VIOV) and SPDR S&P 600 Small CapValue ETF (SLYV). How will NuVasive's stock buyback program work? NuVasive declared that its board has authorized a stock repurchase program on Tuesday, November 9th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.5% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board of directors believes its shares are undervalued. What guidance has NuVasive issued on next quarter's earnings? NuVasive issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.28 billion. What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). What is NuVasive's stock symbol? NuVasive trades on the NASDAQ under the ticker symbol "NUVA." Who are NuVasive's major shareholders? NuVasive's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Thrivent Financial for Lutherans (6.18%), Dimensional Fund Advisors LP (2.78%), Paradice Investment Management LLC (2.67%), Geode Capital Management LLC (1.85%), Arrowstreet Capital Limited Partnership (1.58%) and Point72 Asset Management L.P. (1.57%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link. View institutional ownership trends. How do I buy shares of NuVasive? Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuVasive's stock price today? One share of NUVA stock can currently be purchased for approximately $37.08. How much money does NuVasive make? NuVasive (NASDAQ:NUVA) has a market capitalization of $1.94 billion and generates $1.20 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.71 on an earnings per share basis. How many employees does NuVasive have? The company employs 3,000 workers across the globe. Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More How can I contact NuVasive? NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134. This page (NASDAQ:NUVA) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.